BIS vs. BIB
Compare and contrast key facts about ProShares UltraShort Nasdaq Biotechnology (BIS) and ProShares Ultra Nasdaq Biotechnology (BIB).
BIS and BIB are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. BIS is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (-200%). It was launched on Apr 7, 2010. BIB is a passively managed fund by ProShares that tracks the performance of the NASDAQ Biotechnology Index (200%). It was launched on Apr 7, 2010. Both BIS and BIB are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIS or BIB.
Correlation
The correlation between BIS and BIB is -0.96. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.
Performance
BIS vs. BIB - Performance Comparison
Key characteristics
BIS:
0.58
BIB:
-0.64
BIS:
1.12
BIB:
-0.71
BIS:
1.12
BIB:
0.91
BIS:
0.22
BIB:
-0.38
BIS:
1.07
BIB:
-1.73
BIS:
20.61%
BIB:
13.95%
BIS:
38.01%
BIB:
37.56%
BIS:
-99.77%
BIB:
-67.24%
BIS:
-99.64%
BIB:
-63.03%
Returns By Period
In the year-to-date period, BIS achieves a 20.83% return, which is significantly higher than BIB's -19.95% return. Over the past 10 years, BIS has underperformed BIB with an annualized return of -16.22%, while BIB has yielded a comparatively higher -6.25% annualized return.
BIS
20.83%
32.96%
43.88%
19.05%
-16.61%
-16.22%
BIB
-19.95%
-26.24%
-34.36%
-22.32%
-1.73%
-6.25%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
BIS vs. BIB - Expense Ratio Comparison
Both BIS and BIB have an expense ratio of 0.95%.
Risk-Adjusted Performance
BIS vs. BIB — Risk-Adjusted Performance Rank
BIS
BIB
BIS vs. BIB - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for ProShares UltraShort Nasdaq Biotechnology (BIS) and ProShares Ultra Nasdaq Biotechnology (BIB). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIS vs. BIB - Dividend Comparison
BIS's dividend yield for the trailing twelve months is around 2.99%, more than BIB's 2.34% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
BIS ProShares UltraShort Nasdaq Biotechnology | 2.99% | 3.73% | 1.75% | 0.00% | 0.00% | 0.44% | 2.10% | 0.37% |
BIB ProShares Ultra Nasdaq Biotechnology | 2.34% | 1.69% | 0.07% | 0.03% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
BIS vs. BIB - Drawdown Comparison
The maximum BIS drawdown since its inception was -99.77%, which is greater than BIB's maximum drawdown of -67.24%. Use the drawdown chart below to compare losses from any high point for BIS and BIB. For additional features, visit the drawdowns tool.
Volatility
BIS vs. BIB - Volatility Comparison
The current volatility for ProShares UltraShort Nasdaq Biotechnology (BIS) is 14.84%, while ProShares Ultra Nasdaq Biotechnology (BIB) has a volatility of 15.74%. This indicates that BIS experiences smaller price fluctuations and is considered to be less risky than BIB based on this measure. The chart below showcases a comparison of their rolling one-month volatility.